Company intelligence / Profile preview

Sable Therapeutics

New York, NY, USAsabletherapeutics.com ↗
Ownership
Private
Development stage
Preclinical
01

Overview

Sable Therapeutics has developed novel polycation nanomedicines—SBL‑001 and SBL‑002—that selectively target and reduce the volume of fat cells by up to 70%. These compounds are engineered for high selectivity and can serve as discrete drug delivery systems for additional anti-obesity agents such as GLP‑1 analogues. The company recently entered an exclusive worldwide licensing agreement with Columbia University to advance these assets from laboratory research into clinical development. No published human clinical results yet; programs are transitioning from preclinical to early-stage clinical evaluation

Therapeutic areas
EndocrinologyDermatology
Modalities
NanoparticleSmall molecule
Industry
Biotech
02

Drug pipeline

3 assets

SBL-001

Preclinical

2 more assets in the full pipeline.

Request access →
03

Partnerships

Columbia UniversityShanghai Liuqiang Medical Technology Co. Ltd.Turret Capital Management

Beyond the preview

Go deeper on Sable Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sable Therapeutics.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call